ENLV
Enlivex Therapeutics Ltd.
$0.82
-$0.00(-0.46%)
37
Overall
80
Value
10
Tech
23
Quality
Market Cap
$199.11M
Volume
283.21K
52W Range
$0.66 - $2.10
Target Price
$20.00
Company Overview
| Mkt Cap | $199.11M | Price | $0.82 |
| Volume | 283.21K | Change | -0.46% |
| P/E Ratio | -13.3 | Open | $0.84 |
| Revenue | -- | Prev Close | $0.82 |
| Net Income | $-15.0M | 52W Range | $0.66 - $2.10 |
| Div Yield | N/A | Target | $20.00 |
| Overall | 37 | Value | 80 |
| Quality | 23 | Technical | 10 |
No chart data available
About Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Sector: Healthcare
Industry: Biotechnology
Latest News
3 Best Cheap Stocks to Buy Now: 04/29/26
David Craik•2 days ago
Enlivex Shares Tokenized on Ondo Global Markets to Expand Global Digital Investor Access
TipRanks Auto-Generated Newsdesk•23 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ENLV | $0.82 | -0.5% | 283.21K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Enlivex Therapeutics Ltd. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW